<DOC>
	<DOCNO>NCT01931943</DOCNO>
	<brief_summary>Brief Description : This study design evaluate safety tolerability oral Selatinib Ditosilate Tablets , explore maximum tolerate dose ( MTD ) dose-limiting toxicity patient advance breast cancer .</brief_summary>
	<brief_title>A Phase Ib Study Selatinib Ditosilate Tablets Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>1 . To evaluate safety tolerability oral Selatinib Ditosilate Tablets , explore maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) . 2 . To determine pharmacokinetic profile single multi oral Selatinib Ditosilate Tablets . 3 . To determine preliminary dose regimen phase II study oral Selatinib Ditosilate Tablets . 4 . To assess preliminary antitumor activity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>woman age 1865 . Patients ECOG performance status 0 1 . Expected lifeexpectancy 3 month . Patients must histologically cytologically confirm breast cancer . Either primary breast tumor metastasis must overexpress HER2 ; acceptable method measurement HER2 expression include immunohistochemistry ( IHC ) fluorescence situ hybridization ( FISH ) ; tumor test IHC must 3+ positive HER2 overexpression immunohistochemistry ; tumor test FISH must positive . Prior Herceptin therapy discontinue disease progression patient afford Herceptin therapy . patient least one measurable lesion ( RECIST1.1 criterion ) . Hematology： WBC≥3.5×109/L , ANC≥1.5×109/L , PLT≥100×109/L，HB≥90g/L ; Biochemistry： Serum bilirubin≤1.5 time upper limit normal ( ULN ) , AST ALT ≤1.5 time ULN ; creatinine urea nitrogen≤1.5 time ULN ; LVEF≥50 % , ECG normal , Fridericia correct QT ( QTcF ) ＜470ms . patient receive damage cause therapeutic restored , interval six week since last receiving nitroso mitomycin ; 4 week since last receiving radiotherapy , cytotoxic drug surgery . Subjects swallow normal gastrointestinal function . Female subject agree take contraceptive study within 6 month study ( intrauterine device [ IUD ] , contraceptive drug condom ) ; within 7 day enter study , serum human chorionic gonadotropin negative , must nonlactation period . Ability understand willingness sign write informed consent document . Patients uncontrolled large pleural effusion ascites . Patients receive steroid 50 day , require steroid therapy long time . Requirement therapeutic drug prolong QT interval ( antiarrhythmia drug ) , interrupt . Patients history symptomatic brain metastasis . Patients receive small molecule target drug therapy inhibition HER2 EGFR . Patients participate drug clinical research past 4 week . Pregnant lactate woman exclude study . Patients history allergic reaction attribute compound similar chemical composition agent use study ineligible ; Patients active infection ; Patients cardiac disease include Angina , significant need treat arrhythmia，Myocardial infarction , Heart failure , LVEF &lt; 45 % , heart disease suitable participate study judge investigator . Patients concurrent severe and/or uncontrolled medical condition （including hypertension , severe diabetes , thyroid disease , etc . ) could cause unacceptable safety risk compromise compliance study requirement ineligible . Patients history mental disorder , include epilepsy dementia ineligible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>